出國報告（出國類別：開會）

參加 2024 歐洲世界疫苗大會報告

服務機關：行政院衛生福利部疾病管制署
姓名職稱：林秋香技正/潘施珊護理師
派赴國家/地區：西班牙巴塞隆納
出國期間：113 年 10 月 27 日至 113 年 11 月 10 日
報告日期：113 年 12 月 30 日

摘要

2024 歐洲世界疫苗大會（World Vaccine Congress Europe）於西班牙巴賽隆納舉行，聚焦全球疫苗研發的最新進展，以及在疫苗分配和應用中面臨的全球挑戰與突破。本報告將綜述本次會議的核心議題，特別是抗生素抗藥性（AMR）、癌症疫苗、COVID-19 疫苗與呼吸道融合病毒(RSV)疫苗的研發。會議還討論了針對新興傳染病的應對策略。

在 AMR 方面，大會強調了疫苗在減少抗生素使用和抑制抗生素抗藥性方面的潛力。討論議題包括針對結核、瘧疾和金黃色葡萄球菌等細菌感染的創新疫苗技術。與會專家一致認為，疫苗的應用能夠減少對抗生素的需求，從而有助於控制抗生素抗藥性的蔓延。

癌症疫苗的研究方向聚焦於個性化療法的未來，涵蓋基於新抗原（Neoantigen）的個性化癌症疫苗開發，以及結合免疫調節劑和標靶療法的多平台技術進展。與會者討論了基因編輯和 mRNA 技術在癌症疫苗研發中的創新應用，並探討了這些技術如何推動更精確、個性化的癌症治療方案。

針對 COVID-19 和 RSV 疫苗的討論，涵蓋了對現有疫苗的優化以及新疫苗的研發。與會者分享了 COVID-19 疫苗對抗新變種病毒的能力及其全球覆蓋策略。RSV 疫苗則聚焦於高風險族群（如嬰幼兒和老年人）的保護，並探討了其他新興疫苗的最新臨床試驗結果。

透過專家的分享，與會者深入了解了疫苗佐劑的科學基礎、技術創新及實際應用，並探討了疫苗佐劑在公共衛生中的功用，尤其是在增強疫苗效力和降低資源需求方面的優勢。技術創新如何幫助促進全球公共健康也成為討論的重點，然而，安全性與適應性問題提醒我們，在疫苗開發中需要謹慎評估效力與風險，特別是在針對弱勢族群的應用中。

透過參與疫苗相關的大會，不僅能夠深入了解最新的技術發展和研究成果，還是一個拓展國際視野的重要機會。疫苗大會匯集了來自全球的專家學者、公共衛生領袖以及產業代表，參與其中能接觸到不同國家和地區在疫苗研發、生產和接種策略中的獨特經驗與挑戰，從中汲取最新的科研成果與實際經驗，對未來的疫苗推廣工作也具有極大的幫助。

目次

目的

參與本次會議的主要目的關注於 COVID-19 疫苗及其他新興傳染病疫苗的研發進展、挑戰與未來方向。會議提供新知識及研發技術的交流，涵蓋 mRNA 技術、蛋白疫苗優化，以及疫苗免疫效力和長期保護的最新研究成果，凸顯 COVID-19 大流行對全球公共健康與疫苗技術的深遠影響。

會議旨在加深對疫苗研究、開發及生產領域最新進展的理解，並促進與全球專家的交流與合作。議程涵蓋新興疫苗技術、接種公平性、製造技術和供應鏈管理等廣泛主題，為分享最佳實踐和經驗提供機會。參與專題講座和工作坊將深入探索疫苗研發的新機遇，包括基於 RNA 的疫苗技術、抗生素抗藥性疫苗，以及針對易被忽視疾病的解決方案。此外，會議中特別是針對如 Zika 病毒、抗生素抗藥性（AMR）、猴痘等新興疾病的疫苗研發進展，還討論如何應對氣候變化加劇的傳染病擴散問題。人工智慧、免疫學創新和生物製造技術等加速疫苗研發的關鍵領域亦是討論重點。

參與本次會議，我們期望獲得新知識以促進疫苗的可及性與覆蓋率，提升公眾健康成果。同時，會議強調國際合作的重要性，致力於數據共享、技術轉移及提高中低收入國家疫苗可及性。我們希望通過掌握疫苗發展趨勢，無時差的與全球同步參與應對未來公共衛生危機的策略，為提升全球健康安全作出貢獻。

過程

會議

(一)第一天議程

主題涵蓋 AMR 及癌症疫苗技術、開發、政策與應用等多方面最新研究資訊。各式主題以演講與海報展示，分六大會場同時進行，我們選擇參加不同研究主題與會。

1. 抗生素抗藥性（AMR）：疫苗如何減少抗生素使用及抗藥性。

Evaluating the value of vaccines in reducing AMR- WHO Full Value of Vaccines Study



抗生素抗藥性的負擔

抗生素抗藥性是已被世界衛生組織（WHO）列為全球健康的十大威脅之一，抗生素抗藥性相關的六大主要致病原在 2019 年導致了 357 萬的死亡病例。（262 萬至 478 萬）。

疫苗如何減少抗生素抗藥性

預防感染：疫苗可預防由抗藥性病原體引起的感染，減少個人和群體的發病率。

降低抗生素使用：通過減少感染，減少對抗生素的需求，抑制抗藥性的進化與傳播。





疫苗對 AMR 的影響

提高如肺炎鏈球菌疫苗的接種覆蓋率可避免 59,000 與 AMR 相關的死亡案例。

結核疫苗可能避免 118,000 與 AMR 相關的死亡案例。

如克雷伯氏肺炎桿菌疫苗可避免 64,500 與 AMR 相關的死亡案例。



上圖指出疫苗在減少 AMR 相關死亡方面的重要性，特別是針對肺炎鏈球菌和克雷伯氏肺炎桿菌等病原體所造成的主要感染類型（如下呼吸道、血液感染等）。透過提高這些疫苗的接種覆蓋率，可有效減少與 AMR 相關的死亡。



現有和正在研發中的疫苗每年可避免數十億美元的醫院成本和生產力損失，並顯著減少抗生素用量。



總結

疫苗每年可避免 515,000 人死亡，節省與 AMR 相關的 300 億美元醫療成本，同時減少 25 億劑抗生素用量。強調疫苗在減少 AMR 所帶來的健康、經濟與抗生素使用的巨大負擔，特別是在不同階段的疫苗發展過程中，其效益逐步擴大。



建議
一認可疫苗對減少 AMR 的重要性，並將其納入全球和國家行動計畫；
二加速現有疫苗的引入並提高接種覆蓋率，特別是兒童和老年人群；
三系統性評估新疫苗對 AMR 的影響，並納入政策決策框架；
四推動疫苗研發與實施，將 AMR 指標納入臨床試驗與研究重點，從而全面減少 AMR 的健康和經濟負擔。

2. 為提升疫情防範能力，加速疫苗開發與部署(Improving pandemic preparedness to enable rapid vaccine development and deployment: a consortium initiative by CEPI)

CEPI(Coalition for Epidemic Preparedness Innovations)流行病預防創新聯盟聚焦於如何提升全球應對疫情能力，讓疫苗可以更快開發和分發。CEPI 的目標是實現「100 天內完成疫苗開發」，也就是從病原體被發現到疫苗開發可以使用只需要 100 天。為了達到這個目標，成立監管創新團隊幫助簡化和加速疫苗審核的流程，特別是給需要優先保護的高風險族群。CEPI 使用單一平台技術的方式，可以重複用於多種疫苗，讓開發過程更快、更有效率。此外，該組織製作疫情應對手冊裡面收錄了疫苗開發的最佳做法和策略，幫助疫苗開發者和監管機構合作。
為了確保疫苗公平分配，提出了「同一份檔案、全球同時使用」的方式，並針對可能的風險，比如審核延遲和生產瓶頸，提出解決方案，確保所有國家都能及時獲得疫苗。

3.如何面對持續演化的病毒 A race to cope with a continuously evolving virus







HIPRA BIMERVAX COVID-19 雙價重組蛋白疫苗能快速適應不同 SARS-CoV-2 變異株，可增強免疫反應，並搭配角鯊烯基輔助劑（SQBA）提升免疫效能，提供對多種變異株的保護，已獲得 EMA、UK MHRA 和 WHO 核准。

後續推出的 PHH-1V81 (XBB.1.16) 和 PHH-1V101 (JN.1)也可預防新變異株病毒的感染，預計於 2024-2025 年可以上市使用。新疫苗具備單價與雙價配方，透過異源疫苗接種可聚焦免疫反應，提供長效保護力（可達 365 天），副作用低。此外，該疫苗可在 2-8°C 的冷鏈條件下儲存，無須稀釋，簡化施打流程並提升醫療效率。



臨床試驗證明，該疫苗在中和抗體水平與 T 細胞反應上，表現與 mRNA 疫苗相當或更佳，可能更安全，為未來季節性 COVID-19 疫苗接種提供候選方案。

4. DNA 合成疫苗在個人化癌症治療中的應用



該研究團隊展示新抗原的合成 DNA 疫苗，該疫苗特別對 CD8 T 細胞有強大的免疫反應，對腫瘤產生抑制效果。此外，DNA 疫苗技術已在 COVID-19 疫苗臨床試驗中成功驗證，證明其在臨床應用上的安全性與免疫效果。

動物實驗結果顯示，當 DNA 疫苗設計中包含兩個以上新抗原時，能顯著增強免疫反應並抑制腫瘤生長。該研究團隊將抗腫瘤疫苗與免疫檢查點抑制劑（如 anti-CTLA-4）合用，發現併用療法顯著減緩腫瘤生長並延長存活率。統計結果顯示，治療組與對照組差異顯著，顯示併用療法在臨床應用上的潛力。

整體而言，該研究表明合成 DNA 疫苗具備臨床可行性，能誘導強大的免疫反應，實現個別化治療。同時，該疫苗與免疫檢查點抑制劑聯用可進一步提升治療效果。未來研究將聚焦人體臨床試驗，完善合成 DNA 疫苗技術，為癌症治療帶來新的希望。

(二)第二天議程:

1. 呼吸道融合病毒(RSV)對老年人的威脅 The Burden of Respiratory Syncytial Virus (RSV) Disease among Older Adults



RSV（呼吸道融合病毒）易在老年人中引發嚴重的併發症，與流感和 COVID-19 相比其傳播力更高（R_0達 4.5），並且會導致較高的住院率與死亡率。研究顯示，因 RSV 感染後住院的患者，1 年內存活率僅 74.2%，低於流感患者的 81.2%。RSV 常見症狀包括發燒、流鼻水、鼻塞和咳嗽，容易與其他呼吸道病原混淆，臨床診斷困難。此外，RSV 流行於冬季，與流感及 COVID-19 共同對全球醫療系統造成巨大壓力，尤其成人疫苗接種率不足，使問題更為嚴重。





隨著年齡增長，RSV 的發病率與病程嚴重性（如 ICU 住院與死亡）顯著增加，尤其是合併慢性疾病的患者風險更高。RSV 與流感及 COVID-19 同時流行，對醫療系統造成極大壓力，然而目前疫苗接種率仍然不足。為了降低疾病負擔，成人免疫接種是達成健康老齡化的重要策略，強調疫苗接種能有效預防 RSV 感染高峰。



老年人中 RSV 發生率的低估受到多種因素影響，包括醫療專業人員對 RSV 認識不足、僅在流感季節進行測試的限制、採樣與測試敏感性/特異性低，以及 RSV 發病率在不同地區、族群和季節的高度變異性，導致數據準確性受到挑戰。



此外，美國大多數醫院在處理與下呼吸道感染（LRTI）相關的住院患者時，RSV 測試比例極低，超過 78%的醫院僅在低於 25%LRTI 住院病人中進行 RSV 測試，而整體的中位測試比例僅為 4.3%，顯示對 RSV 的測試和診斷仍然非常不足。



RSV 是造成老年人嚴重呼吸道疾病的重要原因，其發病率和重症風險隨年齡增長及合併症增加而上升。RSV 疫苗接種是實現健康老化與減輕醫療系統壓力的重要策略，能有效降低住院率和重症風險。然而，目前的疫苗接種率仍有提升空間，各國應結合年齡和風險分層制定接種政策。



截至 2024 年 10 月，已有多國已針對不同年齡層制定 RSV 疫苗接種建議，例如≥60 歲（奧地利、波蘭等），≥65 歲（愛爾蘭等），以及≥75 歲（加拿大、法國等）。部分國家也針對高風險族群（如≥18 歲的特定族群）提供疫苗接種建議，並強調政策需隨時更新以應對疫情變化。

2. RSV 候選疫苗（SCB-1019）Phase 1 試驗結果與 GSK 疫苗（AREXVY）的比較

Potential Best-in-Class Bivalent RSV Vaccine Candidate (SCB-1019):Phase 1 Results Head-to-Head Versus GSK vaccine (AREXVY)



Clover SCB-1019 Phase 1: *Immunogenicity Results*

☑ RSV Neutralizing Antibody Titers for Clover's Non-Adjuvanted SCB-1019 Matched GSK's AS01-Adjuvanted AREXVY in RSV-Vaccine Naïve Older Adults (Aged 60-85 Years) at 28 Days Post-Vaccination



Abbreviations: IU/mL (International Units Per Milliliter), GMT (Geometric Mean Titer), GMFR (Geometric Mean Fold Rise).
Note: Bars represent GMTs (± 95% confidence intervals). Data shown for SCB-1019 subjects enrolled at the selected dose level.
RSV neutralization titers expressed as IU/mL calculated using comparison to NIBSC 16/284 reference sera. Assay conducted at third-party testing laboratory using validated RSV neutralization assays.

Clover SCB-1019 Phase 1: *Safety & Reactogenicity Results*

Safety & Reactogenicity Results

☑ Significantly Lower Rates of Local AEs Observed for Clover's non-adjuvanted SCB-1019 (16.7%) Versus GSK's AS01-adjuvanted AREXVY (76.7%)

☑ SCB-1019 Local and Systemic AEs were Generally Mild for SCB-1019 and were Comparable to Saline Placebo

☑ No Vaccine Related Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), or AEs Leading to Discontinuation Observed

☑ Potential Best-in-Class Tolerability Profile



SCB-1019 has a De-Risked & Potential Best-in-Class Combined Efficacy & Safety Profile, with Potential Differentiation to Address Unmet Needs in the Global RSV Vaccine Market (Re-Vaccination & Combo)

☑ Head-to-Head Clinical Results Versus GSK (AREXVY) De-Risks & Indicate Clover's Potential Best-in-Class Combined Efficacy & Safety Profile for SCB-1019 (Non-Adjuvanted Bivalent RSV-A/B Vaccine Candidate)

2025: Planned to Initiate Clinical Trials to Evaluate SCB-1019 in an RSV Re-Vaccination Setting and as Part of a Respiratory Combination Vaccine

此研究重點放在雙價 RSV（呼吸道融合病毒）候選疫苗 SCB-1019 的 Phase 1 臨床試驗結果，並與其他現有的疫苗（如 GSK 的 AREXVY 疫苗）進行比較，針對 RSV-A 和 RSV-B 兩種主要病毒株，第一階段臨床試驗之免疫原性，接種後 28 天，SCB-

1019 產生的中和抗體水平與 GSK 的 AREXVY 疫苗比較是持平甚至更高，特別是在針對 RSV-B 的抗體生成上有顯著優勢。安全性與耐受性方面，SCB-1019 的局部副作用（如接種部位疼痛）的發生率遠低於 GSK 疫苗（16.7% vs.76.7%），不良反應程度輕微且可比於安慰劑。未來，可能成為老年人及高風險群體的另一個防護工具。

3. COVID-19 及相關議題：探討針對新冠的持續挑戰及疫苗開發更新。

Case Study: SARS-CoV-2 Vaccine Improvements



此研究聚焦於改善 SARS-CoV-2 疫苗，使用佐劑來提升 SARS-CoV-2 疫苗的效力。



此實驗將小鼠分兩次接種含 WA1 FL Spike 抗原的疫苗，並分別使用原始株和 Omicron (XBB.1)變異株進行試驗。結果顯示，TLR 佐劑顯著提升免疫反應。數據顯示，使用 TLR 佐劑有助於加強細胞免疫反應，進而提升疫苗對不同變異株的保護力。新型 TLR 佐劑和傳遞系統可提升重組抗原疫苗的免疫反應，並擴展針對季節性變異株的保護範圍。配方類型及新抗原開發均可提高交叉反應性。此外，TLR 佐劑對免疫低下者有效，且具良好的安全性，疫苗的持久性測試正在進行中。



(三)第三天議程:

1.免疫系統的老化對新型疫苗佐劑的反應 Aging impacts on the innate immune response to novel vaccine adjuvants



這張海報探討老化影響免疫系統對新型疫苗佐劑的反應以及如何利用新型疫苗佐劑改善免疫反應。隨著年齡增長，免疫系統的功能會減弱，導致疫苗效力下降和炎症增加。因此，研究團隊使用老年人和年輕人來源的巨噬細胞，分析佐劑在不同年齡群體中對免疫反應的影響。

研究發現，商業佐劑如 AddaVax 能有效激活巨噬細胞中的 NLRP3，特別是在結合 TLR4 和 TLR7/8 激時顯示更強的免疫促進作用。然而，老年人的巨噬細胞相較於年輕人顯示出較低的細胞死亡率，反映出老化對免疫反應的特殊調控。這些結果強調，針對老年人的疫苗設計應考慮佐劑的選擇與組合。
總結來說，此研究表明新型佐劑可能改善老年人的免疫反應，未來需多評估疫苗佐劑對不同年齡群體的效果，對未來疫苗開發具有重要意義。

2. 第二代瘧疾疫苗 A second-generation malaria vaccine



GSK 和世界衛生組織（WHO）在對抗瘧疾方面的重要進展，特別是第一代瘧疾疫苗（Mosquirix）及其未來第二代疫苗的研究與實施計劃。Mosquirix 疫苗已在非洲多國實施接種，覆蓋超過 230 萬名兒童，顯著降低了瘧疾相關的死亡率和重症比例。然而，由於疫苗接種覆蓋率有限（3 劑覆蓋率 65%，4 劑不到 50%），疫苗接種覆蓋仍有進步空間。


Final impact results from Malaria Vaccine Implementation Programme (MVIP)
Across Ghana, Kenya and Malawi over 46 months of implementation
World Health Organization
13% (2-22%) reduction in all-cause mortality
22% (4% - 37%) reduction in severe malaria
Measured in children age-eligible for vaccination
Population-based estimate: 3-doses vaccine coverage ~65%; 4-dose coverage < 50%
Observed in areas with good ITN use, good access to care
Potentially even higher impact where preventive and curative services are less reliable
Shows that high impact can be gained by preventing malaria early when children most vulnerable
MVIP and RTS,S served as a pathfinder for second and next-generation malaria vaccines
Mayuko
PATH-WHO MVIP call, 31 Oct 2023


Overview of the GSK baseline and Phase IV epidemiological studies
2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Start of Vaccine Implementation
EPI-MAL-002 BASELINE
EPI-MAL-003 VACCINE USE
IA
FA
Incidence rate of meningitis, AESIs, death and malaria (including cerebral malaria)
Safety monitoring and effectiveness of RTS,S/AS01
EPI-MAL-005: Annual survey & EPI-MAL-010: Strain Replacement
• Parasite prevalence and use of malaria control interventions
• Evaluation of parasite genetic diversity
MVPE (WHO)
Safety monitoring and effectiveness of RTS,S/AS01 feasibility of implementation
IA Interim analysis & report
FA Final analysis & report
GSK
ClinicalTrials;NCT02374450;2020;1-15 (EPI-MAL-002), Clinicaltrials.gov;NCT03855995;2021;1-16 (EPI-MAL-003), ClinicalTrials;NCT02251704;2020;1-9 (EPI-MAL-005) (Accessed October 2021)
31 October 2024
3



現有疫苗有效率第一年僅為 60-70%，保護期較短且需要多次加強劑，限制了預防疾病的效果。第二代疫苗目標是提高效能（12 個月內超過 90%），延長保護期，並降低生產和接種成本。策略包括優化抗原設計，開發多階段抗原，以提升疫苗免疫反應的穩定性與持久性，並採用單瓶多劑量配方來簡化供應鏈。





第二代疫苗將擴展至更廣泛的年齡層，包括 6 至 10 歲的兒童和年輕成人，並評估其在降低寄生蟲傳播和感染率方面的效果。此外，結合型疫苗的開發可能進一步減輕瘧疾的全球負擔。





第二代瘧疾疫苗目的在解決現有疫苗的不足，包括效能、保護期及成本問題，同時開發新的受益群體與更高效率的接種方式。加速開發過程與降低成本是實現廣泛覆蓋的核心目標。

3. Vaccines Europe 最新疫苗研發趨勢及未來研發重點領域





未來疫苗開發針對重點健康問題，包括：

抗生素抗藥性（AMR）：通過預防感染減少抗生素濫用，有 15 個候選疫苗專注於抗生素抗藥性。

氣候變遷與新興病原體：開發針對瘧疾、登革熱、黃熱病及新型病毒的疫苗。

人畜共患病與疫情準備：如狂犬病和禽流感疫苗。







透過技術多樣化提升疫苗效能與覆蓋率。其研究針對不同年齡群體需求，強調全生命周期免疫的重要性，並通過國際合作與數位化技術推動疫苗開發，致力於改善全球健康並應對未來風險。



疫苗項目聚焦於不同年齡群體的需求，包括兒童、成人及老年人，並探索孕期免疫的新策略。未來的疫苗研發將結合數位化技術和創新平台，以應對人口老化、抗藥性和全球性疫情等挑戰。

心得及建議

本次參加 2024 歐洲世界疫苗大會，深入了解了全球疫苗開發的最新進展及其對公共健康的深遠影響。會議聚焦於新興傳染病、抗生素抗藥性（AMR）、疫情準備及氣候變遷等關鍵議題。根據 Vaccines Europe 的報告，目前全球共有 103 個疫苗候選項目正在開發，其中 42%專注於尚無疫苗覆蓋的疾病，反映出國際社會對公共健康威脅的高度重視與積極應對。

在會議期間，針對抗生素抗藥性和 COVID-19 疫苗的最新研究進展給我們留下深刻印象。這些領域與我國的公共衛生策略密切相關，特別是歐洲多國透過疫苗研發合作，在抗生素抗藥性及多病原聯合疫苗開發方面取得的重要突破，可為我們提供寶貴的經驗借鑒。建議持續指派負責疫苗業務的承辦人員參與類似的國際疫苗會議，以掌握疫苗研發的最新進展和他國衛生政策動向。這不僅有助於了解歐洲及其他先進國家的疫苗開發趨勢，還可促進國際技術引進與合作。此次大會的參與，不僅加深了我們對全球疫苗研發趨勢的認識，也為未來如何有效應對疫苗可預防傳染病之潛在威脅，提供了重要的啟發。

附錄

Agenda at-a-glance

Hyperlinked section headers – click to quickly navigate detailed agenda by topic

Pre-Congress Workshops – Monday 28th October					
Morning Workshops: 10:00-13:00					
Platform Technologies			Biothreats & Disease X		
Lunch & Networking Break: 13:00-14:00					
Afternoon Workshops: 14:00-17:00					
Mucosal & Alternative Delivery			Vaccine Equity		
Day 1 – Tuesday 29th October					
Morning Keynotes: 09:00-10:40					
Expo & Networking Break: 10:40-11:10					
Working Groups: 11:10-12:10					
Expo & Networking Break: 12:10-13:40			Start-Up Pitches: 12:20-13:10		
			Poster Presentations: 13:10-13:40		
Track Presentations: 13:40-15:10					
Technology Showcases	COVID & Beyond	Formulation & Bioprocess	AMR & Bacterial Vaccines	Pre-Clinical Development	Immune Profiling
Expo & Networking Break: 15:10-15:40					
Track Presentations: 15:40-16:55					
Technology Showcases	COVID & Beyond	Formulation & Bioprocess	AMR & Bacterial Vaccines	Pre-Clinical Development	Immune Profiling
Comfort Break: 16:55-17:10					
Closing Keynote: 17:10-18:00					
Offsite Networking, terrace of the Museu Nacional d'Art de Catalunya: 18:45					
Day 2 – Wednesday 30th October					
Morning Keynotes: 09:00-10:40					
Expo & Networking Break: 10:40-11:10					
Track Presentations: 11:10-12:40					
Clinical Trials	One Health & Veterinary	Respiratory	Emerging & Infectious Disease	AMR & Bacterial Vaccines	Bioprocess & Manufacturing
Expo & Networking Break: 12:40-14:10			Working Groups: 13:00-14:00	Start-Up Pitches: 13:00-13:40	
				Poster Presentations: 13:40-14:10	
Track Presentations: 14:10-16:40					
Clinical Trials	One Health & Veterinary	Respiratory	Emerging & Infectious Disease	AMR & Bacterial Vaccines	Bioprocess & Manufacturing
Expo & Networking Break: 16:40-17:10					
Closing Keynote: 17:10-18:00					
Exhibition Networking Drinks: 18:00					
Day 3 – Thursday 31st October					
Expo & Networking Break: 09:00-09:30					
Track Presentations: 09:30-11:30					
Manufacturing Technologies	Partnerships & Access	Supply & Logistics	Cancer & Therapeutic	NDs & Global Health	Clinical Trials
Expo & Networking Break: 11:30-12:30					
Track Presentations: 12:30-14:45					
Manufacturing Technologies	Partnerships & Access	Supply & Logistics	Cancer & Therapeutic	NDs & Global Health	Clinical Trials
Comfort Break: 14:45-15:00					
Closing Keynote: 15:00-16:00					
END OF CONGRESS					

DAY 1 – Tuesday 29th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance	KEYNOTES
Registration Opens: 07:45	
Morning Keynotes: 09:00-10:40	
Strengthening Global Preparedness and Building Resilient Health Systems: Meeting Pandemic and Epidemic Demands Strategies for Achieving Global Immunization Equity: How Soon Can We Make It a Reality?	
Expo & Networking Break: **10:40-11:10**	
Working Groups: **11:10-12:10**	
Expo & Networking Break: 12:10-13:40 Join us in the exhibition hall for: 1-2-1 partnering, refreshments, start-up pitches & poster sessions	Start-Up Pitches: **12:20-13:10** *Theatre 1* Poster Presentations: **13:10-13:40** *Poster Zone, Exhibition Floor*
Track Presentations: **13:40-15:10**	
Technology Showcases *Theatre 2* **COVID & Beyond** *Theatre 3* **Formulation & Bioprocess** *Theatre 1* **AMR & Bacterial Vaccines** *Theatre 4* **Pre-Clinical Development** *Theatre 5* **Immune Profiling** *Theatre 6*	
Expo & Networking Break: 15:10-15:40	
Track Presentations: **15:40-16:55**	
Technology Showcases *Theatre 2* **COVID & Beyond** *Theatre 3* **Formulation & Bioprocess** *Theatre 1* **AMR & Bacterial Vaccines** *Theatre 4* **Pre-Clinical Development** *Theatre 5* **Immune Profiling** *Theatre 6*	
Comfort Break: **16:55-17:10**	
Closing Keynote: 17:10-18:00	
Can uptake keep up with the speed of vaccine developments?	

DAY 1 – Tuesday 29th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Technology Showcases	COVID & Beyond	Formulation & Bioprocess	AMR & Bacterial Vaccines	Pre-Clinical Development	Immune Profiling

Technology Showcases

Theatre 2

Chair: Prof Jonathan Heeney, Professor, Comparative Pathology, Head, Laboratory of Viral Zoonotics, University of Cambridge, CEO, DIOSynVax

13:40	New tricks for 190 kb of genomic DNA in the cytoplasm: MVA as a viral vector for Personalized Vaccines and Pandemic Response Dr. Volker Sandig, CSO, ProBioGen AG.
13:55	Accelerating Multivalent Mrna Vaccine Development: Rapid Construct Characterization & Protein Expression Analysis With Vaxarray® Senior Representative, Biomérieux
14:10	Capturing high quality immunoassay data- case studies using Certimmune Dr Andrea Tattersall, Director, Lab Operation, Revvity
14:25	Navigating The Future of Vaccine Manufacturing with Molecular Devices Dr Kristyna Sala, Applications Scientist for Imaging & BioPharma, Molecular Devices
14:40	Development Of A Safe And Effective Ebola Vaccine – Title TBC Senior Representative, Invitria
14:55	A scalable cell-free protein production technology accelerating vaccine development Dr Ricarda Finnern, Chief Scientific Officer, Leniobio Gmbh
	15:10-15:40 - Afternoon Expo & Networking Break
15:40	NE01 Intranasal Adjuvant: Phase 1 H5N1 Influenza Immunogenicity and Safety Results Dr Chad Costley, CEO & President, Blue Willow Biologics
15:55	
16:10	AI-designed vaccine based on mRNA technology that protects against a broad range of betacoronaviruses Dr Kaïdre Bendjama, CSO, NEC OncoImmunity AS
16:25	
16:40	The Future of Injectables: A Vaccine through BFS Manufacturing is Possible PJ Kim, Vice President of Business Development, Apiject
16:55	END OF TRACK

DAY 1 – Tuesday 29th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Technology Showcases	COVID & Beyond	Formulation & Bioprocess	AMR & Bacterial Vaccines	Pre-Clinical Development	Immune Profiling

COVID & BEYOND

Theatre 3

Sponsored by BioNTech

Chair: Dr Jerry Sadoff, CMO, Centivax - TBC

13:40	Capillary Devices for Sample Collection in Decentralized Vaccine Studies Kelli Aufderheide, Director, Decentralized Trial Laboratory Solutions, Q² Solutions
13:55	
14:10	Optimized Prime: A Transformative RNA-LNP Vaccine Composition that Scales Dr Martin Rabel, Services Solution Specialist, Cytiva
14:25	
14:40	COVID-19 protein vaccines: A race to cope with a continuous evolving virus Dr Alexandra Moros, Project Leader & Researcher in R&D, Human Health Division, HIPRA
14:55	
	15:10-15:40 - Afternoon Expo & Networking Break
15:40	Title TBC Senior Representative, Croda
15:55	Oral Covid Vaccine - Clinical Update from phase 1 to phase 2B Dr James Cummings, Chief Medical Officer, Vaxart
16:10	Panel: Outstanding questions about long COVID Moderator: Dr Walter Straus, VP, Clinical Safety, Moderna Dr Sultan Abduljawad, Global Scientific Affairs Advisor, BioNTech Stefan Schreck, Head Of Unit, Health Programme And Chronic Diseases, European Commission
16:25	
16:40	
16:55	END OF TRACK

DAY 1 – Tuesday 29th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance | KEYNOTES

Technology Showcases | COVID & Beyond | Formulation & Bioprocess | AMR & Bacterial Vaccines | Pre-Clinical Development | Immune Profiling

AMR & Bacterial Vaccines

Theatre 4

Chair: Dr Jan Poolman, Former Head Bacterial Vaccine Discovery and Early Development, Johnson & Johnson

13:40	**WHO Full Value of Vaccines Study**
13:55	Dr Mateusz Hasso-Agopsowicz, Technical Officer & Project Manager, Vaccine Product & Delivery Research Immunization, Vaccines and Biologicals (IVB), WHO
14:10	**Panel: Demonstrating value and introducing 'vaccines against AMR' into policy framework**
14:25	- How are we considering the evidence of the value of vaccines against AMR in vaccine recommendations?
14:40	
14:55	- What additional evidence is needed to inform policy and regulatory changes? - The impact of viral vaccines on antibiotic usage and AMR incidence, how are we measuring this? Moderator: Dr Jan Poolman, Former Head Bacterial Vaccine Discovery and Early Development, Johnson & Johnson Dr Rino Rappuoli, Scientific Director, Fondazione Biotecnopolo di Siena Charlotte Vernhes, Director, Scientific and Medical Affairs, Vaccines Europe, EFPIA Dr Collin Brown, Deputy Director of Clinical & Emerging Infections, UKHSA – TBC Ivo Claassen, Head of Veterinary Medicines Division, EMA // Dr Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, EMA – TBC Dr Richard Alm, CSO, Carb-X – invited
	15:10-15:40 - Afternoon Expo & Networking Break
15:40	**The African Genome: Crafting Vaccines for a Diverse Continent** Justin Devine, Co-Founder and Chief Innovation Officer, Synexa Life Sciences
15:55	**Panel: Vaccines as an alternative to antimicrobials in animals**
16:10	- Current landscape of antimicrobial use in animals
16:25	- What are our alternatives: Vaccines, Phages, etc.
16:40	- Can vaccination be a cost-effective solution? - Financing models and incentives to develop and use alternatives to antimicrobials - How to encourage the use of alternatives to antibiotics in livestock and aquaculture? Moderator: Dr Jan Poolman, Former Head Bacterial Vaccine Discovery and Early Development, Johnson & Johnson Dr Holy Akwar, Deputy Head of AMR & VP, WOAH Dr David Farcas, Project Director, Yelcho Prof Eric Fevre, Chair of Veterinary Infectious Diseases, The University of Liverpool Dr Jeremy Salt, CEO, The Vaccine Group
16:55	**END OF TRACK** — CONT: AMR DAY 2

Workshops | DAY 1 | DAY 2 | DAY 3

DAY 1 – Tuesday 29th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance | KEYNOTES

Technology Showcases | COVID & Beyond | Formulation & Bioprocess | AMR & Bacterial Vaccines | Pre-Clinical Development | Immune Profiling

Immune Profiling

Theatre 6

Chair: Dr Galit Alter, VP of Immunology Research, Moderna

13:40	**Correlates of protection in the CoV002 trial of ChAdOx1.nCOV19 (Vaxzevria): A Systems Serology analysis** Dr Lenny Moise, VP Research, SeromYx Systems
13:55	
14:10	**Characterizing vaccine-induced immune responses with ELISpot and FluoroSpot assays** Dr Tyler Sandberg, Product Manager, Mabtech
14:25	**How Luminex's xMAP INTELLIFLEX will boost your vaccine development** Senior Representative, Luminex Corporation, A *DiaSorin Company*
14:40	**Vaccine responses in the elderly population** Dr Francesco Berlanda Scorza, VP, Global Health R&D Vaccines Head and GVGH Institute Director, GSK - TBC
14:55	**The Importance Of Adjuvants In Improving Vaccine Responses In Elderly And Immunocompromised** Dr Margherita Coccia, Director, Adjuvant Science and Technology, GSK
	15:10-15:40 - Afternoon Expo & Networking Break
15:40	**AI enabled immune-profiling to quantify and track vaccine efficacy. Generative AI for accelerated vaccine development** Dr Holger Heyn, Co-Founder & CSO, Omniscope Dr Christian Brander, ICREA Senior Research Professor, IrsiCaixa & Omniscope
15:55	
16:10	**Combining Microneedle Patch Delivery with the Shigella flexneri 2a GMMA vaccine** Dr Jae Myun Lee, Head Professor and Chair of Microbiology & Immunology, Yonsei University, College of Medicine, & Scientific Advisor, QuadMedicine Inc.
16:25	**Antigens Derived From Microorganisms Showing Molecular Mimicry Of Tumor Associated Antigens** Dr Luigi Buonaguro, PI, Istituto Nazionale Tumori Pascale
16:40	**Human in vitro modeling for age-specific adjuvanted vaccine discovery and development** Dr Ofer Levy, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Professor, Harvard Medical School
16:55	**END OF TRACK**

Workshops | DAY 1 | DAY 2 | DAY 3

DAY 2 – Wednesday 30th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance	KEYNOTES

Registration Opens: 08:00

Morning Keynotes: 09:00-10:40

Turning Target To Treatment: What Is The Pathway From A Priority Pathogen List To Vaccines?
From Zika To Zoonotic A: Anticipating And Combating Climate-Accelerated Infectious Diseases

Expo & Networking Break: 10:40-11:10

Track Presentations: 11:10-12:40

Clinical Trials *Theatre 5*	One Health & Veterinary *Theatre 6*	Respiratory *Theatre 3*	Emerging & Infectious Diseases *Theatre 2*	AMR & Bacterial Vaccines *Theatre 4*	Bioprocess & Manufacturing *Theatre 5*

Expo & Networking Break: 12:40-14:10
Join us in the exhibition hall for:
1-2-1 partnering, refreshments, start-up pitches & poster sessions

Working Groups: **13:00-14:00**
See room allocations below

Start-Up Pitches: **13:00-13:40**
Theatre 1

Poster Presentations: **13:40-14:10**
Poster Zone, Exhibition Floor

Track Presentations: 14:10-16:40

Clinical Trials *Theatre 5*	One Health & Veterinary *Theatre 6*	Respiratory *Theatre 3*	Emerging & Infectious Diseases *Theatre 2*	AMR & Bacterial Vaccines *Theatre 4*	Bioprocess & Manufacturing *Theatre 1*

Expo & Networking Break: 16:40-17:10

Closing Keynote: 17:10-18:00

The Evolving Definition of Protection: Progress and Prospects in Therapeutic Vaccines & Immune Modulation

DAY 2 – Wednesday 30th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Clinical Trials	One Health & Veterinary	Respiratory	Emerging & Infectious Diseases	AMR & Bacterial Vaccines	Bioprocess & Manufacturing

Respiratory

Theatre 3

Chair: Dr Bassam Hallis, Deputy Director, Vaccine Development & Evaluation Centre, UKHSA

11:10 11:25	Baseline biomarkers of immunogenicity & reactogenicity to influenza vaccine in over 65s – Title TBC Dr Ali Harandi, Head, Vaccine Evaluation Research Lab, University of Gothenburg & Visiting Associate Professor, Vaccine Evaluation Center, The University of British Columbia
11:40 11:55	Challenges of universal flu & coronavirus vaccines Dr Jay Evans, Chief Scientific & Strategy Officer, Inimmune & Director, Center for Translational Medicine, University of Montana
12:10	Preclinical and clinical evaluation of a novel RSV B-based prefusion stabilized F protein vaccine candidate Dr Roland Zahn, Senior Scientific Director, Head of Translational & Pre-Clinical Immunology – Viral Vaccines, Johnson & Johnson
12:25	Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate – Title TBC Dr Alexandre Le Vert, Chief Executive Officer, Osivax
	12:40-14:10 - Lunch Expo & Networking Break
14:10 14:25	New advances in respiratory virus challenge models improving their value for vaccine efficacy testing and host response disease monitoring Dr Andrew Catchpole, CSO, hVIVO
14:40	Potent And Differentiated Bivalent RSV Vaccine In Older Adults Dr Nicolas Burdin, Global Head of R&D, Clover Biopharmaceuticals
14:55	Vaccination in pregnancy: use in RSV & COVID Dr Jenny Hendriks, Head Biomarkers Viral Vaccines and Ad Interim Head Clinical Immunology, Janssen Vaccine and Prevention BV
15:10 15:25	MSD RSV Clinical Programme Updates Dr Andrea Guerra, Regional Clinical Director, Vaccines, MSD Prof Heather Zar, Professor & Head, Department of Paediatrics and Child Health & Director, School of Child and Adolescent Health, University of Cape Town (UCT)
15:40	Update on Novavax Investigational Influenza vaccine and COVID-19-INFLUENZA Combination Vaccine Development Dr Vivek Shinde, VP, Clinical Development, Novavax
15:55	Metavac®-RSV: in vivo Proof of Concept of first Intranasal vaccine against RSV and HMPV Denis Cavert, CEO, Vaxxel
16:10 16:25	Where are we with adult respiratory combination vaccines? Dr Helen Nicholls, Director, Medical Monitor, Vaccine Clinical Research and Development, Pfizer
16:40	END OF TRACK

DAY 2 – Wednesday 30th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Clinical Trials	One Health & Veterinary	Respiratory	Emerging & Infectious Diseases	AMR & Bacterial Vaccines	Bioprocess & Manufacturing

Emerging & Infectious Diseases

Theatre 2

Chair: Dr Swati Gupta, Vice President, Head of Emerging Infectious Diseases and Scientific Strategy, IAVI

11:10	Advancements in Human Metapneumovirus (hMPV) Vaccine Research Dr Marta Murreddu, Project Manager, Viroclinics, a Cerba Research Company
11:25 11:40	Cutaneous jet injection of naked mRNA for safe and effective vaccination against infectious diseases Prof Satoshi Uchida, Professor, Tokyo Medical and Dental University & Chief Medical Officer, Crafton Biotechnology
11:55	A quadrivalent mRNA-lipid nanoparticle vaccine broadly protects against diverse *Orthopoxviruses* Dr Alec Freyn, Principal Scientist, Virology, Moderna
12:10	AI-Immunology™ for vaccine target discovery, design and development (TBC) Thomas Trolle, Director of Bioinformatics and AI/ML, Evaxion Biotech
12:25	Reducing Vaccine-Induced Immunological Cross-Reactivity Between Flaviviruses Vaccines Dr Sebastian Ulbert, Deputy Director & Head Department of Vaccines and Infection Models, Fraunhofer Institute for Cell Therapy and Immunology
	12:40-14:10 - Lunch Expo & Networking Break
14:10 14:25	A Novel, Single-dose, Live, Attenuated, Minimally Replicating Mpox Vaccine Dr Zeil Rosenberg, Executive Vice President, Tonix Pharmaceuticals
14:40 14:55	IAVI's Lassa vaccine candidate and the challenges of doing a field efficacy study in West Africa Dr Marion Gruber, Vice President of Public Health & Regulatory Affairs, IAVI & Former Director, Office of Vaccines Research and Review, CBER/FDA
15:10 15:25	Design and proof of principle in a mouse model of a promising vaccine for Zika virus currently in Phase I clinical trial Prof Lance Turtle, Chair and Honorary Consultant Physician in Infectious Diseases; Deputy Head, Department of Clinical Infection, Microbiology and Immunology, University of Liverpool
15:40 15:55 16:10 16:25	Panel: Post-authorization safety and effectiveness evaluation of vaccines deployed under emergency use authorization - Diseases (e.g. Ebola, Malaria, Dengue) that are associated with outbreaks and are not established as endemically with vaccines that have/are being developed - How should the global health community consider evaluation of these vaccines outside of clinical trials leading to EUA? Moderator: Dr Walter Straus, VP, Clinical Safety, Moderna Prof Miriam Sturkenboom, President, VAC4EU & Professor of Real World Evidence & Head, Department of Data Science and Biostatistics, Julius Center, UMC Utrecht Dr Gabrielle Breugelmans, Director of Epidemiology and Data Science, CEPI Dr Bradford Powell, Lead Scientific Advisor, Blu Zone Bio
16:40	**END OF TRACK**

DAY 2 – Wednesday 30th October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance | KEYNOTES

Clinical Trials | One Health & Veterinary | Respiratory | Emerging & Infectious Diseases | AMR & Bacterial Vaccines | Bioprocess & Manufacturing

AMR & Bacterial Vaccines

Theatre 4

Chair: Dr Jan Poolman, Former Head Bacterial Vaccine Discovery and Early Development, Johnson & Johnson

11:10 11:25 11:40	**Panel: Where are we with current TB vaccine efforts?** - Predicted the impact of novel vaccines on disease burden and AMR - Including AMR surveillance during TB Vaccine trials - Reaching communities most effect by TB, are we considering cost and delivery? Moderator: Dr Jan Poolman, Former Head Bacterial Vaccine Discovery and Early Development, Johnson & Johnson Dr Marion Gruber, Vice President of Public Health & Regulatory Affairs, IAVI & Former Director, Office of Vaccines Research and Review, CBER/FDA Dr Ruben Rizzi, Senior Vice President, Global Regulatory Affairs, BioNTech Dr Nick Jackson, CEO, Novo Nordisk Foundation Initiative for Vaccines & Immunity (NIVI)
11:55	**Clinical Development of MTBVAC, a live attenuated MTb vaccine** Dr Bernard Fritzell, Independent Consultant, Tuberculosis Vaccine Initiative
12:10	**Update on the Ph3 E.coli/ExPEC vaccine** Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Johnson & Johnson
12:25	**Establishing bacterial vaccine priorities: *S. aureus*** Dr Suzanne Welten, Scientific Manager Immunology, J&J innovative Medicine
	12:40-14:10 - Lunch Expo & Networking Break
14:10	**Progress towards a vaccine against Klebsiella** Dr Francesco Berlanda Scorza, VP, Global Health R&D Vaccines Head and GVGH Institute, GSK
14:25	**Novel Mucosal Approaches in Bacterial Vaccine Development: Klebsiella Nasal Vaccine and Oral Strategies for ETEC and Polio** Dr Elizabeth Norton, Associate Professor, Department of Immunology & Micrology, Tulane University
14:40	**A Novel Vaccine Against Neisseria Gonorrhoeae** Dr Michael Kowarik, CSO, Limmatech
14:55	**Vaccine progress towards Group A Strep** Dr Helge Dorfmueller, PI, Molecular Microbiology, University of Dundee
15:10 15:25	**Intranasal Immunization: Device and Formulation Promises and Challenges- Title TBC** Lucas Silva, Senior Specialist, Nanopharm, an Aptar Pharma company Nektaria Karavas, Global Director, BD, Nasal Vaccines, Antivirals and Immuno-stimulants, Aptar Pharma
15:40 15:55 16:10 16:25	**Panel: The Role of Vaccines & mAbs in Neonatal Sepsis Prevention** - Overview of the epidemiology, disease burden and current vaccine & mAb development for neonatal sepsis. - Biological complexities of major neonatal sepsis pathogens: Klebsiella and Group B Streptococcus, including serotype diversity and resistance profiles. - Comparing maternal vs infant immunisation strategies - Potential impacts of RSV maternal vaccination outcomes on future messaging & uptake. - Identifying priorities for future research and strategies to enhance neonatal sepsis prevention. Dr Timothy Cooke, CEO, Omniose Dr Michael Kowarik, CSO, Limmatech Dr Simona Rondini, Head Bacterial Projects and Senior Project Leader, GSK Dr Stephen Lockhart, Director, Senior Consultant, Hurst Grange Associates Dr Bengt Johansson Lindbom, CSO, Minervax Prof Paul Heath, Co-Founder, Centre for Neonatal and Paediatric Infection // Prof Shabir Madhi, Dean, Faculty of Health Sciences & Professor of Vaccinology, University of the Witwatersrand & Director, (VIDA) - invited
16:40	**END OF TRACK**

Workshops | DAY 1 | DAY 2 | DAY 3

Day 3 – Thursday 31st October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance					KEYNOTES
Registration Opens: 08:30 *(TBC)*					
Expo & Networking Break: 09:00-09:30					
Track Presentations: **09:30-11:30**					
Manufacturing Technologies *Theatre 1*	Partnerships & Access *Theatre 2*	Supply & Logistics *Theatre 6*	Cancer & Therapeutic *Theatre 3*	Neglected Disease & Global Health *Theatre 4*	Clinical Trials *Theatre 5*
Expo & Networking Break: 11:30-12:30 Join us in the exhibition hall for: 1-2-1 partnering & poster sessions					
Track Presentations: **12:30-14:45**					
Manufacturing Technologies *Theatre 1*	Partnerships & Access *Theatre 2*	Supply & Logistics *Theatre 6*	Cancer & Therapeutic *Theatre 3*	Neglected Disease & Global Health *Theatre 4*	Clinical Trials *Theatre 5*
Comfort Break: **14:45-15:00**					
Closing Keynote: 15:00-16:00					
Will AI Define Tomorrow's Vaccines? Insights into Tech-driven Innovations					
END OF CONGRESS					
Workshops	DAY 1	DAY 2	DAY 3		

Day 3 – Thursday 31st October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Manufacturing Technologies	Partnerships & Access	Supply & Logistics	Cancer & Therapeutic	Neglected Disease & Global Health	Clinical Trials

Cancer & Therapeutic Vaccines

Theatre 3

Sponsored by GenScript

Chair: Dr Niranjan Sardesai, CEO, Geneos Therapeutics

09:30	Targeting mKRAS Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity: Preliminary Results from the Phase 1 AMPLIFY-201 Trial Robert Connelly, CEO / Dr Pete DeMuth, CSO, Elicio Therapeutics - TBC
09:45	Personalized cancer vaccines beyond neoantigens (title to be confirmed) Dr Birgitte Rønø, Chief Scientific Officer, Evaxion Biotech
10:00 10:15	Neoantigen Immunotherapy for Solid Tumors: Molecular Responses and Clinical Benefit in End-Stage Patients – Title TBC Dr Karin Jooss, EVP & Head of R&D, Gritstone Bio
10:30 10:45	FiCAT, A Next Generation Gene Writing Platform for Advanced Therapies. Dr Avencia Sanchez-Mejias, CEO & Co-Founder, Integra Therapeutics *on behalf of GenScript*
11:00 11:15	BioNTech's oncology pipeline: combining cancer vaccines with immunomodulators & targeted therapies Dr Uta Tschiesner, Sr Director, Global Medical Advisor, BioNTech
	11:30-12:30 - Expo & Networking Break
12:30 12:45	CAMYO-01: colorectal cancer-specific camyotypes formulated into an mRNA vaccine Cedric Bogaert, Co-Founder and CEO, MyNEO Therapeutics
13:00 13:15	Bioinformatic Capabilities For Clonal Neoantigen Selection Andrew Craig, SVP, Bioinformatics & Data Science, Achilles Therapeutics
13:30 13:45	Targeting multiple neoantigens in personalized cancer vaccines Dr Niranjan Sardesai, CEO, Geneos Therapeutics
14:00 14:15	mRNA-4157 Individualized Neoantigen Therapy: mRNA therapeutics coming of age in cancer Senior Representative (TBC), Moderna
14:30	NOUS-209 genetic vaccine encoding shared neoantigens for treatment and interception of MSI tumors Dr Elisa Scarselli, CSO / Dr Morena D'Alise, VP of Immunology, Nouscom - TBC
14:45	END OF TRACK

Workshops	DAY 1	DAY 2	DAY 3

Day 3 – Thursday 31st October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Manufacturing Technologies	Partnerships & Access	Supply & Logistics	Cancer & Therapeutic	Neglected Disease & Global Health	Clinical Trials

Neglected Disease & Global Health

Theatre 4

Chair: Dr Marlene Espinoza, Director & Product Development Lead, Emerging Infectious Diseases, IAVI

09:30	**Chagas Disease**
09:45	Dr Maria Elena Bottazzi, Co-Director, Texas Children's Hospital for Vaccine Development, Baylor College of Medicine
10:00	**Multi-pathogen vaccination to address challenges in LMICs – Title TBC**
10:15	Dr Hans Keirstead, CEO, AIVITA Biomedical & CEO, Human Immunome Project
10:30	**Vaccines for a sustainable planet: Insights from Palio**
	Dr Francesco Berlanda Scorza, VP, Global Health R&D Vaccines Head and GVGH Institute Director, GSK
10:45	**A strategy blueprint to combat the superbug Neisseria gonorrhoeae**
	Prof Aleksandra Sikora, Professor, College of Pharmacy, Oregon State University & Adjunct Professor, Vaccine and Gene Therapy Institute, Oregon Health and Science University
11:00	**New saponin adjuvant for global health cost effectiveness – Title TBC**
11:15	Dr Gerben Marsman, Project Manager, Vaccine Formulation Institute
	11:30-12:30 - Expo & Networking Break
12:30	**Structure-based vaccine design for malaria antigens & progress on second-gen malaria vaccines**
	Dr Katie Ewer, Senior Project Leader, Malaria Vaccines, GSK Vaccines
12:45	**Panel: Advancing Malaria Vaccine Development: Public-Private Partnerships, Novel Technologies, and Multistage**
13:00	**Strategies**
13:15	- Current strategies for developing the next-generation malaria vaccines
13:30	- What exciting prospects do novel technologies present for advancing malaria vaccine development, especially multistage vaccines? - Accelerating malaria vaccine development through public-private partnerships Moderator: Dr Irene Nailain Nkumama, Malaria programme Manager, European Vaccine Initiative Dr Katie Ewer, Senior Project Leader, Malaria Vaccines, GSK Vaccines Dr Thierry Rolling, Director, Clinical Development, BioNTech Prof Sumi Biswas, Group Leader, Transmission Blocking Malaria Vaccine, University of Oxford & Co- Founder & CSO, SpyBiotech Prof Meta Roestenberg, Clinical Head, Controlled Human Infection Center, Leiden University
13:45	**Panel: Bridging Gaps in Global Health: Building a Sustainable Vaccine Production Ecosystem in Latin America**
14:00	- What type of manufacturing capabilities need to be established to take ownership of vaccine production and distribution within the region?
14:15	- Adopting and innovating new tech to enhance self-reliance and reduce dependency on global supply chains
14:30	- The importance of strategic regional partnerships; addressing challenges in knowledge transfer, and building sustainable local expertise in vaccine production - Strategies for creating a sustainable and resilient vaccine manufacturing ecosystem - Examination of the regulatory frameworks governing vaccine manufacturing in LATAM; Challenges in harmonizing regulations across the region to streamline manufacturing processes Dr Maria Elena Bottazzi, Co-Director, Texas Children's Hospital for Vaccine Development, Baylor College of Medicine Dr Dagmar García Rivera, Vice Director, Research and Development, The Finlay Institute of Vaccines Dr Jorge Osorio, Professor, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison & President and CEO, VaxThera – TBC Analia Acebal, Consultant, Sustainable Vaccine Manufacturing Lead, CEPI & CEO & Founder, NoLimit Bio - TBC Elvira Zini, Director of Scientific & Technical Affairs, Laboratorios Richmond SACIF - TBC
14:45	**END OF TRACK**

Day 3 – Thursday 31st October

Fira de Barcelona, Montjuic

Agenda-At-A-Glance			KEYNOTES		
Manufacturing Technologies	Partnerships & Access	Supply & Logistics	Cancer & Therapeutic	Neglected Disease & Global Health	Clinical Trials

Manufacturing Technologies

Theatre 1

Chair: Arlene Joyner, Director, Industrial Base Management and Supply Chain, Administration for Strategic Preparedness and Response, US Department of Health and Human Services

09:30	**Development, Scale-Up, and Manufacture of an Oncolytic Virus Vaccine** Senior Representative, APC Ltd.
09:45 10:00 10:15	**Panel: Global Implications of the BIOSECURE Act** - What global efforts are being made to integrate and ensure global manufacturing capacity? - Will the EU follow suit and implement similar policies? Moderator: Taylor Sexton, Executive Director, Medical Counter Measures Col (Ret) Vic Suarez, Founder and Principal Growth Partner, Blu Zone Bio Arlene Joyner, Director, Industrial Base Management and Supply Chain, Administration for Strategic Preparedness and Response, US Department of Health and Human Services Sankarasubramanian Rajaram, Head of Global Medical Strategy, CSL Seqirus - TBC *Invited*: Olivier Girard, Head, Medical Counter Measures, HERA, European Commission
10:30 10:45 11:00	**Vaccines On Demand: How Far Can We Downsize Modular Manufacturing?** Dr Daniel Wolfe, Branch Chief, CBRN Vaccines, BARDA Analia Acebal, Consultant, Sustainable Vaccine Manufacturing Lead, CEPI & CEO & Founder, NoLimit Bio - TBC Senior Representative, General Electric & Nature's Toolbox – TBC
11:15	**Title TBC** Senior Representative, TECIL
	11:30-12:30 - Expo & Networking Break
12:30 12:45	**Mathematical Modelling Tools to Accelerate Vaccine R&D and Manufacturing** Dr Irina Meln, Project and Innovation Manager, European Vaccine Initiative Dr Michelangelo Canzoneri, Global Head of Group Smart Manufacturing, Merck – TBC Prof Martina Micheletti, Co-Director, EPSRC Vaccine Manufacturing Hub For A Sustainable Future & EPSRC/DHSC Future Vaccine Manufacturing Hub, UCL – TBC
13:00	**New Technologies for Flu Vaccines. Better Vaccines?** Dr Robert C Huebner, Principal Consultant, Latham Biopharm Group
13:15	**Highly Multiplexed, 30-minute VaxArray® Immunoassay for Pneumococcal Vaccine Antigen Characterization** Senior Representative, bioMérieux
13:30 13:45	**Measles-Rubella Microarray Patches & MAP Technologies – Title TBC** Dr Ajoy Chakrabarti, Portfolio & Platform Lead, Polio, Global Health Program, Bill & Melinda Gates Foundation
14:00	**From Formulation to Function: Closing Current Gaps in Microarray Development: TBC** Professor Anne Moore, Principal Investigator, University College Cork
14:15 14:30	**Applying Analytical Technologies to Support Process Development** Dr Gautam Sanyal, Principal Consultant & Founder, Vaccine Analytics
14:45	END OF TRACK